Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00237809 · ClinicalTrials.gov registry record · Phase 3
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
A Phase 3 study of Schizophrenia and Schizoaffective Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
- 2
- Study locations
NCT00237809: Completed Phase 3 study of Schizophrenia and Schizoaffective Disorder, sponsored by Yale University.
NCT00237809 is a Phase 3 study of Schizophrenia and Schizoaffective Disorder that has completed, run by Yale University. The registered enrollment target is 104 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00237809, a Phase 3 study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.
Primary Outcome
The WCST allows the clinician to speculate to the following "frontal" lobe functions: strategic planning, organized searching, utilizing environmental feedback to shift cognitive sets, directing behavior toward achieving a goal, and modulating impulsive responding. The test can be administered to those from 6.5 years to 89 years of age.The test takes approximately 12-20 minutes to carry out and generates a number of psychometric scores, including numbers, percentages, and percentiles of: categor
Conditions Studied
Interventions
- DRUG Placebo
- DRUG D-serine
- BEHAVIORAL Cognitive Retraining (CRT)
- BEHAVIORAL Cognitive Retraining Placebo
Study Locations (2)
Connecticut
- Connecticut Mental Health Center - New Haven
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2002-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
What the finished NCT00237809 record still lists
NCT00237809 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (53% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00237809 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00237809 about?
NCT00237809 is a clinical study titled "D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia". This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained bene...
What is the current status of trial NCT00237809?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2002-09. Estimated completion is 2012-09.
What conditions does trial NCT00237809 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT00237809?
The interventions under investigation include: Placebo (DRUG), D-serine (DRUG), Cognitive Retraining (CRT) (BEHAVIORAL), Cognitive Retraining Placebo (BEHAVIORAL).
Who is sponsoring clinical trial NCT00237809?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00237809 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00237809's enrollment target sits among peer trials
104 136th of 315 higher than 179 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia